A new experimental drug, lepodisiran, developed by Eli Lilly, has shown a significant reduction in lipoprotein(a) [Lp(a)] levels—by an impressive…
Read More »
A new experimental drug, lepodisiran, developed by Eli Lilly, has shown a significant reduction in lipoprotein(a) [Lp(a)] levels—by an impressive…
Read More »